Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -30.64%66.29M | 103.17%279.62M | 178.30%95.58M | 1,110.83%137.62M | 5,119.30%34.34M | 457.70%11.37M | 313.84%658K | --2.04M | --159K | ---- |
| Operating income | -30.64%66.29M | 103.17%279.62M | 178.30%95.58M | 1,110.83%137.62M | 5,119.30%34.34M | 457.70%11.37M | 313.84%658K | 2.04M | 159K | |
| Cost of sales | 24.35%-34.23M | -104.39%-136.15M | -245.79%-45.24M | -1,843.26%-66.62M | -6,281.95%-13.08M | -700.93%-3.43M | -120.43%-205K | ---428K | ---93K | ---- |
| Operating expenses | 24.35%-34.23M | -104.39%-136.15M | -245.79%-45.24M | -1,843.26%-66.62M | -6,281.95%-13.08M | -700.93%-3.43M | -120.43%-205K | -428K | -93K | |
| Gross profit | -36.30%32.07M | 102.04%143.46M | 136.76%50.34M | 794.53%71.01M | 4,593.16%21.26M | 393.04%7.94M | 586.36%453K | 1.61M | 66K | |
| Selling expenses | 11.43%-91.66M | -26.57%-263.66M | -78.33%-103.49M | -479.70%-208.31M | -871.08%-58.03M | -471.11%-35.93M | -463.24%-5.98M | ---6.29M | ---1.06M | ---- |
| Administrative expenses | 4.96%-64.25M | 23.68%-141.87M | 23.12%-67.6M | -85.05%-185.89M | -113.71%-87.93M | -55.15%-100.45M | -30.43%-41.15M | -131.96%-64.75M | ---31.55M | ---27.91M |
| Research and development expenses | 20.33%-78.88M | 7.73%-199.05M | -9.84%-99.01M | -19.34%-215.71M | -8.00%-90.14M | -63.49%-180.76M | -66.46%-83.46M | 31.72%-110.56M | ---50.14M | ---161.93M |
| Revaluation surplus | ---- | ---- | ---- | -344.60%-1.45B | -732.67%-1.45B | -171.83%-327.1M | -397.74%-174.65M | -358.61%-120.33M | ---35.09M | --46.53M |
| -Changes in the fair value of financial assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---35.09M | --46.53M |
| -Changes in the fair value of other assets | ---- | ---- | ---- | -344.60%-1.45B | -732.67%-1.45B | -171.83%-327.1M | ---174.65M | ---120.33M | ---- | ---- |
| Impairment and provision | ---7.18M | 42.82%-430K | ---- | ---752K | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other impairment is provision | ---7.18M | 42.82%-430K | ---- | ---752K | ---- | ---- | ---- | ---- | ---- | ---- |
| Special items of operating profit | -203.62%-24.54M | 11.37%38.59M | -22.37%23.68M | -57.84%34.65M | -43.28%30.5M | 539.37%82.19M | 819.48%53.78M | 66.61%-18.71M | ---7.48M | ---56.02M |
| Operating profit | -19.56%-234.44M | 78.41%-422.95M | 88.03%-196.08M | -253.59%-1.96B | -552.82%-1.64B | -73.69%-554.11M | -100.41%-251.01M | -60.05%-319.02M | -125.25M | -199.33M |
| Financing cost | -2.15%-4.95M | -142.57%-10.86M | -182.40%-4.85M | -159.09%-4.48M | -182.24%-1.72M | -209.12%-1.73M | -261.90%-608K | 6.68%-559K | ---168K | ---599K |
| Earning before tax | -19.14%-239.39M | 77.91%-433.81M | 87.75%-200.93M | -253.30%-1.96B | -551.93%-1.64B | -73.93%-555.84M | -100.62%-251.61M | -59.85%-319.58M | -125.42M | -199.93M |
| After-tax profit from continuing operations | -19.14%-239.39M | 77.91%-433.81M | 87.75%-200.93M | -253.30%-1.96B | -551.93%-1.64B | -73.93%-555.84M | -100.62%-251.61M | -59.85%-319.58M | -125.42M | -199.93M |
| Earning after tax | -19.14%-239.39M | 77.91%-433.81M | 87.75%-200.93M | -253.30%-1.96B | -551.93%-1.64B | -73.93%-555.84M | -100.62%-251.61M | -59.85%-319.58M | -125.42M | -199.93M |
| Minority profit | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---29.82M |
| Profit attributable to shareholders | -19.14%-239.39M | 77.91%-433.81M | 87.75%-200.93M | -253.30%-1.96B | -551.93%-1.64B | -73.93%-555.84M | -100.62%-251.61M | -87.87%-319.58M | -125.42M | -170.11M |
| Basic earnings per share | -13.64%-0.75 | 85.31%-1.41 | 95.83%-0.66 | -38.33%-9.6 | -404.46%-15.84 | -73.93%-6.94 | 59.90%-3.14 | 67.13%-3.99 | -7.83 | -12.14 |
| Diluted earnings per share | -13.64%-0.75 | 85.31%-1.41 | 95.83%-0.66 | -38.33%-9.6 | -404.46%-15.84 | -73.93%-6.94 | 59.90%-3.14 | 69.02%-3.99 | -7.83 | -12.88 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.